New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
10:00 EDTSCMP, RNA, PTCT, CBAY, SRPT, BIN, FLML, CWST, SGMO, PZG, FINL, ANETOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at Citigroup... Casella Waste (CWST) initiated with a Hold at Stifel... CymaBay Therapeutics (CBAY) initiated with an Outperform at Cowen... Finish Line (FINL) initiated with a Buy at Jefferies... Flamel Technologies (FLML) initiated with an Outperform at Leerink... PTC Therapeutics (PTCT) initiated with an Outperform at Oppenheimer... Paramount Gold & Silver (PZG) initiated with a Buy at Noble Financial... Progressive Waste (BIN) initiated with a Hold at Stifel... Prosensa (RNA) initiated with an Outperform at Oppenheimer... Sangamo (SGMO) initiated with an Overweight at JPMorgan... Sarepta (SRPT) initiated with an Outperform at Oppenheimer... Sucampo (SCMP) initiated with a Buy at Roth Capital.
News For ANET;CWST;CBAY;FINL;FLML;PTCT;PZG;BIN;RNA;SGMO;SRPT;SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 24, 2014
09:20 EDTSRPT, RNAProsensa buyout not good for Sarepta, says Piper Jaffray
Piper Jaffray says it views the Prosensa (RNA) acquisition by BioMarin (BMRN) as bad for Sarepta (SRPT) since the company now has to compete with a "significantly more experienced and better funded orphan drug player." Piper adds that the takeover announced this morning has no impact on Sarepta's current drug filing process for its Duchenne muscular dystrophy drug eteplirsen. It keeps a Neutral rating on Sarepta with a $20 price target. The stock is trading up 9% in pre-market trading to $17.16 after BioMarin paid a healthy premium to acquire its peer Prosensa.
09:20 EDTRNABioMarin says Prosensa deal does not reflect deterioration of pipeline
Subscribe for More Information
08:17 EDTPTCTPTC Therapeutics to hold annual science day
Subscribe for More Information
08:12 EDTSRPT, RNASarepta rises after DMD competitor acquired at significant premium
Shares of Sarepta Therapeutics (SRPT) are up 9.5% to $17.23 in early pre-market trading after rival drugmaker Prosensa (RNA) agreed to be acquired by BioMarin (BMRN). BioMarin has offered to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680M. In addition, two approximately $80M contingent milestones are payable for the approval of drisapersen in the U.S. and Europe. Drisapersen is Prosensa's lead exon-skipping drug candidate for treating Duchenne muscular dystrophy, or DMD. Sarepta is at work on eteplirsen, its own exon-skipping therapeutic candidate for the treatment of DMD. Prosensa closed trading Friday at $11.44 and are up about 65% to $18.90 in pre-market trading following the deal announcement.
06:44 EDTRNABioMarin to host conference call
Subscribe for More Information
06:02 EDTRNABioMarin agrees to purchase all shares of Prosensa for $17.75 per share
Subscribe for More Information
November 20, 2014
15:14 EDTSRPTTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
November 19, 2014
08:10 EDTPZGParamount Gold & Silver expands bulk tonnage potential at San Miguel
Subscribe for More Information
08:03 EDTPTCTPTC to receive $10M milestone payment from Roche as SMA program advances
Subscribe for More Information
07:08 EDTSGMOSangamo says study demonstrates in vivo reversal of Huntington's disease signs
Subscribe for More Information
November 18, 2014
09:17 EDTSRPTSarepta announces first patient dosed in Eteplirsen study
Subscribe for More Information
07:37 EDTSCMPStifel to hold a conference
Subscribe for More Information
07:36 EDTANETUBS to hold a conference
Global Technology Conference to be held in Sausalito, California on November 18-20 with webcasted company presentations to begin on November 18 at 10:45 am; not all company presentations may be webcasted. Webcast Link
November 17, 2014
11:49 EDTSGMOPiper Jaffray healthcare analysts to hold an analyst/industry conference call
Subscribe for More Information
10:02 EDTBINOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: CyrusOne (CONE) upgraded to Buy from Hold at Stifel... MGIC Investment (MTG) upgraded to Conviction Buy from Buy at Goldman... NuVasive (NUVA) upgraded to Outperform from Market Perform at Wells Fargo... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Pinnacle Foods (PF) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Outperform from Sector Perform at RBC Capital.. Thoratec (THOR) upgraded to Outperform from Market Perform at Wells Fargo... Volcano (VOLC) upgraded to Outperform from Neutral at Credit Suisse... Progressive Waste (BIN) upgraded to Neutral from Underperform at Macquarie... Clean Harbors (CLH) upgraded to Outperform from Neutral at Wedbush... McGraw Hill Financial (MHFI) upgraded to Buy from Hold at Benchmark Co... Chesapeake (CHK) upgraded to Outperform from Market Perform at Bernstein... American Science & Engineering (ASEI) upgraded to Fair Value from Sell at CRT Capital... Sony (SNE) upgraded to Overweight from Equal Weight at Morgan Stanley.
08:44 EDTSRPTNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
07:04 EDTBINProgressive Waste upgraded to Neutral from Underperform at Macquarie
Subscribe for More Information
07:04 EDTRNAProsensa reports Q3 EPS (EUR 0.29) vs. (EUR 0.12) last year
November 16, 2014
17:10 EDTANETArista Networks growth could slow, Barron's says
Subscribe for More Information
November 14, 2014
16:19 EDTRNAGIMV reports 1.43% passive stake in Prosensa
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use